In short
This article discusses the ongoing clinical trials investigating Debio 0123, a highly selective inhibitor of the WEE1 kinase, for the treatment of advanced solid tumors. The trials aim to evaluate the safety, efficacy, and optimal dosing of Debio 0123 alone and in combination with other drugs. These studies focus on patients with specific genetic alterations, including CCNE1 amplification and FBXW7 mutations, and explore the potential of Debio 0123 in various cancer types, including glioblastoma and ovarian cancer.
At a glance
- Drug Name
- Debio 0123
- Drug Type
- Highly selective inhibitor of the WEE1 kinase
- Administration
- Oral (hard capsules)
- Target Conditions
- Advanced solid tumors, glioblastoma, high-grade serous ovarian cancer
- Genetic Targets
- CCNE1 amplification, FBXW7 mutations, PPP2R1A mutations
- Trial Phases
- Phase 1/1b and Phase 2
- Key Objectives
- Safety, tolerability, optimal dosing, pharmacokinetics, preliminary efficacy
- Combination Therapies
- Temozolomide, RP-3500
- Patient Age Range
- 12 years and older (varies by trial module)
- Primary Endpoints
- Adverse events, dose-limiting toxicities, pharmacokinetics, tumor response
What is Debio 0123?
Debio 0123 is an investigational drug being developed for the treatment of various advanced solid tumors. It is classified as a highly selective inhibitor of the WEE1 kinase. The drug is currently being studied in clinical trials to evaluate its safety and effectiveness in treating certain types of cancer.
How Does Debio 0123 Work?
Debio 0123 works by targeting a specific protein in cancer cells called WEE1 kinase. This protein plays a crucial role in regulating the cell cycle, which is the process by which cells grow and divide. By inhibiting WEE1 kinase, Debio 0123 aims to disrupt the cancer cells' ability to repair DNA damage and divide properly, potentially leading to their death.
What Conditions Does Debio 0123 Treat?
Debio 0123 is being investigated for the treatment of various advanced solid tumors, particularly those with specific genetic characteristics. The clinical trials are focusing on patients with:
- Glioblastoma (GBM): A type of aggressive brain cancer
- Advanced solid tumors with specific genetic alterations, including:
- CCNE1 amplification
- Deleterious mutations in FBXW7
- Other proprietary gene mutations
- High-grade serous ovarian, fallopian tube, or primary peritoneal cancer
Clinical Trials and Research
Debio 0123 is currently being studied in several clinical trials:
- Glioblastoma Study: A phase 1/2 trial is investigating Debio 0123 in combination with temozolomide (TMZ) for patients with recurrent or newly diagnosed glioblastoma. This study aims to:
- Determine the safety and tolerability of the combination
- Find the appropriate dose for further investigation
- Assess the drug's effectiveness against glioblastoma
- Advanced Solid Tumors Study (MYTHIC): A phase 1/1b trial is examining Debio 0123 alone and in combination with other drugs for patients with advanced solid tumors. This study focuses on:
- Evaluating the safety and tolerability of Debio 0123
- Determining the best dose and schedule for treatment
- Assessing the drug's effectiveness against various types of solid tumors
Administration and Dosage
Debio 0123 is administered orally in the form of hard capsules. The exact dosage and schedule are still being determined through the ongoing clinical trials. Patients participating in these studies will receive specific instructions from their healthcare providers regarding how and when to take the medication.
Potential Side Effects
As Debio 0123 is still in the investigational stage, the full range of potential side effects is not yet known. The clinical trials are designed to assess the safety profile of the drug and identify any adverse events. Some general side effects that are being monitored include:
- Changes in blood cell counts
- Liver function abnormalities
- Gastrointestinal issues
- Fatigue
- Potential effects on heart rhythm (QT interval prolongation)
It's important to note that patients participating in clinical trials are closely monitored for any side effects, and the researchers take necessary precautions to ensure patient safety.
Conclusion
Debio 0123 represents a promising new approach in the treatment of advanced solid tumors, particularly those with specific genetic characteristics. While still in the investigational stage, the ongoing clinical trials aim to establish its safety and efficacy. Patients with eligible conditions who have exhausted standard treatment options may want to discuss with their oncologists whether participating in a clinical trial involving Debio 0123 could be appropriate for their situation.